elasomeran · Spikevax

Vaccine

Approvedregulatory verdict

Evidence outlook

Approved: COVID-19

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older (conditional marketing authorisation)
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (12)
COVID-19
NCT05815498 · ModernaTX, Inc.
2023-03-28 – 2025-04-12 · COVID-19
What this study did
NCT06354998 · ModernaTX, Inc.
2024-04-08 – 2024-05-10 · SARS-CoV-2
What this study did
NCT05119855 · Merck Sharp & Dohme LLC
2022-03-28 – 2023-12-12 · Papillomavirus Infections, Coronavirus Disease (COVID-19)
What this study did
NCT05148845 · Wits Health Consortium (Pty) Ltd
2021-11-10 – 2023-06-30 · SARS CoV 2 Infection
What this study did
NCT05543356 · Murdoch Childrens Research Institute
2022-05-02 – 2022-11-30 · COVID-19
What this study did
NCT05228730 · Murdoch Childrens Research Institute
2022-05-02 – 2022-11-30 · COVID-19
What this study did
Other / comorbidity
NCT04805125 · University Hospital, Basel, Switzerland
2021-04-19 – 2023-09-23 · Immunocompromised Patients
What this study did
NCT05158140 · Merck Sharp & Dohme LLC
2022-01-12 – 2023-02-21 · Pneumococcal Infection
What this study did
Phase 2/3 (5)
COVID-19
NCT04649151 · ModernaTX, Inc.
2020-12-09 – 2024-06-14 · SARS-CoV-2
What this study did
NCT05168813 · COVID-19 Prevention Network
2021-12-01 – 2024-04-19 · SARS-CoV-2 Infection, HIV Infections, COVID-19
What this study did
NCT04927065 · ModernaTX, Inc.
2021-05-28 – 2023-11-17 · SARS-CoV-2
What this study did
NCT05249829 · ModernaTX, Inc.
2022-02-16 – 2023-06-23 · SARS-CoV-2
What this study did
Phase 2 (10)
COVID-19
NCT05584202 · ModernaTX, Inc.
2022-09-30 – 2024-11-15 · SARS-CoV-2
What this study did
NCT05000216 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-08-13 – 2024-03-28 · Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
What this study did
NCT05289037 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-03-30 – 2023-11-27 · COVID-19
What this study did
NCT05160766 · Oliver Cornely, MD
2021-11-08 – 2023-09-13 · Prevention of COVID-19
What this study did
NCT04847050 · National Cancer Institute (NCI)
2021-04-28 – 2023-05-25 · Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma, Multiple Myeloma
What this study did
NCT04969263 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-08-10 – 2023-03-10 · Kidney Transplant Recipients
What this study did
NCT04748471 · Assistance Publique - Hôpitaux de Paris
2021-02-10 – 2023-01-25 · Prevention of COVID19
What this study did
NCT04852978 · Regeneron Pharmaceuticals
2021-04-29 – 2022-11-21 · Healthy, Chronic Stable Illness
What this study did
Phase 1/2 (4)
COVID-19
NCT04889209 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-05-28 – 2023-06-16 · COVID-19
What this study did
NCT05132855 · Chang Gung Memorial Hospital
2021-11-30 – 2023-04 · COVID-19, Breakthrough Infection
What this study did
NCT05375838 · ModernaTX, Inc.
2022-05-13 – 2022-12-29 · SARS-CoV-2, Influenza
What this study did
Other / comorbidity
NCT05280158 · University of California, Los Angeles
2022-03-10 – 2023-02-27 · Lung Transplant Recipient, SARS-CoV-2, Immunosuppression
What this study did
Phase 1 (5)
COVID-19
NCT05420077 · RVAC Medicines (US), Inc.
2022-09-12 – 2023-06-02 · Infectious Disease, COVID-19
What this study did
NCT04785144 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-03-31 – 2022-07-05 · COVID-19, COVID-19 Immunisation
What this study did
NCT04283461 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-03-16 – 2022-04-26 · COVID-19, COVID-19 Immunisation
What this study did
Other / comorbidity
NCT05397223 · ModernaTX, Inc.
2022-05-24 – 2026-02-27 · SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
What this study did
Phase 4 (12)
COVID-19
NCT06585241 · ModernaTX, Inc.
2024-09-09 – 2026-12-31 · SARS-CoV-2
What this study did
NCT07863635 · ModernaTX, Inc.
2026-10-09 – 2026-12-11 · SARS-CoV-2
What this study did
NCT05075538 · Jules Bordet Institute
2021-12-01 – 2024-01-08 · Cancer
What this study did
NCT04952402 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-07-09 – 2023-01-10 · Covid19, SARS-CoV2 Infection
What this study did
NCT05079633 · National Taiwan University Hospital
2021-09-30 – 2023-01-10 · Covid19 Vaccine
What this study did
NCT04969250 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-08-25 – 2022-12-21 · Covid19
What this study did
NCT06189040 · Universiteit Antwerpen
2021-05-26 – 2022-07-08 · Coronavirus Disease 2019, COVID-19
What this study did
NCT05030974 · University Medical Center Groningen
2021-10-21 – 2022-03-12 · Covid19, Kidney Diseases, Vaccine Response Impaired, SARS-CoV2 Infection
What this study did
NCT04885907 · University Health Network, Toronto
2021-05-25 – 2021-08-30 · Vaccine Response Impaired, Immune Suppression, Covid19
What this study did
Other / comorbidity
NCT04792567 · Novartis Pharmaceuticals
2021-04-19 – 2022-08-15 · Secondary Progressive Multiple Sclerosis
What this study did
Early phase / not applicable (1)
COVID-19
NCT04715438 · University Medical Center Groningen
2021-01-08 – 2025-04 · Cancer
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
COVID-19
NCT05048940 · Instituto de Investigación Marqués de Valdecilla
2021-09-01 – 2021-09-01 · Covid19
What this study did
Phase 2 (7)
COVID-19
NCT05383560 · Sheba Medical Center
2022-09-05 – 2024-01-31 · COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection, COVID-19
What this study did
NCT04894435 · Canadian Immunization Research Network
2021-06-11 – 2023-06-16 · COVID-19
What this study did
NCT05345873 · Sinocelltech Ltd.
2022-07-01 – 2023-04-01 · COVID-19, SARS-CoV-2 Infection
What this study did
NCT05137236 · ModernaTX, Inc.
2021-12-06 – 2023-03-23 · SARS-CoV-2
What this study did
NCT05324319 · Medical University of Vienna
2021-06-15 – 2022-12-31 · COVID-19
What this study did
NCT05197153 · Medigen Vaccine Biologics Corp.
2022-01-22 – 2022-10-28 · COVID-19 Vaccine
What this study did
Other / comorbidity
NCT07808697 · ModernaTX, Inc.
2026-09-04 – 2029-08-30 · SARS-CoV-2
What this study did
Phase 4 (1)
COVID-19
NCT07790523 · Tor Biering-Sørensen
2026-09-01 – 2028-09-30 · COVID-19, Influenza
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
COVID-19
NCT05315362 · Leiden University Medical Center
2022-05-01 – 2023-05-01 · Vaccination; Infection, COVID-19
What this study did

Competitive landscape

This drug's own stage for COVID-19: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Elasomeran (Spikevax): this drugApprovedVaccineSARS-CoV-2 spike proteinReliable signalNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2not yet gradedNo reviewed efficacy summary in this indication
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistnot yet gradedNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed
NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36)
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasenot yet gradedNo reviewed efficacy summary in this indication
IbuzatrelvirPhase 3Small moleculeSARS-CoV-2 3CL proteasenot yet gradedNo reviewed efficacy summary in this indication
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
MasitinibPhase 2Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
GSK4396687
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Spikevax (elasomeran) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 4COVID-19Recruiting
Est. primary completion 2026-12-11 · NCT07863635 · CT.gov ↗
What to watch
Phase 4COVID-19Recruiting
Est. primary completion 2026-12-31 · NCT06585241 · CT.gov ↗
What to watch
2027 (1)
June 2027 (1)
Phase 4COVID-19Active not recruiting
Est. primary completion 2027-06-16 · NCT07266558 · CT.gov ↗
What to watch

See the full readout calendar ↗